HSBC maintains a Buy rating on Gilead Sciences; PT raised to $175
Benzinga/TradingView data show HSBC raised its Gilead Sciences price target to $175.00 a share from $155.00 while maintaining a Buy rating. The action is attributed to HSBC.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.